Innate Pharma S.A. (OTCMKTS:IPHYF – Get Free Report)’s stock price fell 19.6% on Friday . The stock traded as low as $2.13 and last traded at $2.13. 2,000 shares changed hands during mid-day trading, an increase of 278% from the average session volume of 529 shares. The stock had previously closed at $2.65.
Innate Pharma Trading Down 19.6 %
The stock’s 50-day simple moving average is $2.61 and its 200-day simple moving average is $2.62.
About Innate Pharma
Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.
Read More
- Five stocks we like better than Innate Pharma
- 3 Best Fintech Stocks for a Portfolio Boost
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- What is the NASDAQ Stock Exchange?
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- Investing in large cap stocks: Diving into big caps
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.